An Immunomodulatory Device Improves Insulin Resistance in Obese Porcine Model of Metabolic Syndrome

Figure 5

Analysis of circulating levels of TNFα was completed for MET03 and MET04 before each treatment (pretreatment), immediately after each 6-hour treatment period (posttreatment), and day 1, week 1, and week 2 following the third treatment. A decrease in TNFα was consistently observed from pretreatment to posttreatment, with high significance achieved () when averaging all pretreatment (A, B, and C) levels () and comparing to all posttreatment (A, B, and C) averaged levels (), providing strong evidence that SCD therapy is able to reduce the chronic systemic inflammation associated with MetS as presented in this model.